Completed PHASE3 INTERVENTIONAL 1-arm NCT00128505

An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

Sponsor: Corcept Therapeutics

Conditions Major Depressive Disorder Psychotic Disorders

Interventions Mifepristone

Updated 7 times since 2017 Last updated: Feb 14, 2012 Started: Aug 31, 2005 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Major Depressive Disorder and Psychotic Disorders and is currently completed. Corcept Therapeutics leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corcept Therapeutics

Data source: Corcept Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belgrade, Serbia , Bucharest, Romania , Kragujevac, Serbia , Novi Sad, Serbia , Osijek, Croatia , Rijeka, Croatia , Sofia, Bulgaria , Split, Croatia , Târgu Mureş, Romania , Varna, Bulgaria and 1 more location